Skip to content

Efficacy, safety and economic evaluation of Dangguijagyak-san for primary dysmenorrhea; a randomized, double-blind, parallel-group, multi-center, investigator-initiated clinical trial

Efficacy, safety and economic evaluation of Dangguijagyak-san for primary dysmenorrhea; a randomized, double-blind, parallel-group, multi-center, investigator-initiated clinical trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CRIS
Registry ID
KCT0003005
Enrollment
240
Registered
2018-07-16
Start date
2018-10-22
Completion date
Unknown
Last updated
2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Participants will administer DJS, GSS, or placebo powder orally three times a day for two menstrual cycles according to the group allocated

Sponsors

Kyung Hee University Oriental Medicine Hospital at Gangdong
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: The inclusion criteria are: (1) reproductive-age female aged = 18 and = 40 years; (2) suffering from primary dysmenorrhea; (3) suffering from menstrual pain within recent three consecutive months and average VAS = 50 mm during run-in period; (4) being provided with the details of this trial, understanding the details completely, willing to participate voluntarily, and being offered written informed consent to follow the precautions.

Exclusion criteria

Exclusion criteria: The exclusion criteria are: (1) women suffering from secondary dysmenorrhea due to pelvic pathology such as uterine fibroids, adenomyosis, endometriosis, or pelvic inflammatory diseases; (2) lactating, being pregnancy, intend to be pregnant, or have possibility of pregnancy (human chorionic gonadotropin test positive); (3) with intrauterine devices; (4) metrorrhagia with menstrual cycles less than 21 days or oligomenorrhea with cycles over 40 days; (5) have administered oral contraceptives or other hormonal treatments within recent three months; (6) twice higher liver enzymes (alanine transaminase or aspartate transaminase) than the reference values of study sites; (7) 1.5 times higher blood urea nitrogen or creatinine than the reference values of study sites; (8) have depressive or anxiety disorders, or administrating psychiatric medications such as antidepressants; (9) have participated in other clinical trials within recent one month; (10) have been treated with Chinese herbal medicines or alternative therapies for primary dysmenorrhea within recent three months; (11) judged inadequate by investigators.

Design outcomes

Primary

MeasureTime frame
VAS(Visual analogye scale)

Secondary

MeasureTime frame
VMSS(Verbal multidimensional scoring system);RSS(Retrospective symptom scale);Short form McGill pain questionnaire (SF-MPQ);pattern diagnosis questionaaire(Qi stagnation pattern, Blood stasis pattern);short form 36 health survey (SF-36);adverse event;vital sign;laboratory test;EuroQol Rive dimesions Questionnaire(EQ-5D);iMTA Productivity Cost Questionnaire(iPCQ)

Countries

Korea, Republic of

Contacts

Public ContactEun Jeong Jeong

Kyung Hee University Oriental Medicine Hospital at Gangdong

yellowbow@hanmail.net+82-2-440-7128

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 19, 2026